Cargando…

In vivo engineering of a human vasculature for bone tissue engineering applications

The neovascularization of three-dimensional voluminous tissues, such as bone, represents an important challenge in tissue engineering applications. The formation of a preformed vascular plexus could maintain cell viability and promote vascularization after transplantation. We have developed a three-...

Descripción completa

Detalles Bibliográficos
Autores principales: Steffens, Lilian, Wenger, Andreas, Stark, G Björn, Finkenzeller, Günter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516493/
https://www.ncbi.nlm.nih.gov/pubmed/18624770
http://dx.doi.org/10.1111/j.1582-4934.2008.00418.x
_version_ 1782383071973081088
author Steffens, Lilian
Wenger, Andreas
Stark, G Björn
Finkenzeller, Günter
author_facet Steffens, Lilian
Wenger, Andreas
Stark, G Björn
Finkenzeller, Günter
author_sort Steffens, Lilian
collection PubMed
description The neovascularization of three-dimensional voluminous tissues, such as bone, represents an important challenge in tissue engineering applications. The formation of a preformed vascular plexus could maintain cell viability and promote vascularization after transplantation. We have developed a three-dimensional spheroidal coculture system consisting of human primary endothelial cells and human primary osteoblasts (hOBs) to improve angiogenesis in bone tissue engineering applications. In this study, we investigated the survival and vascularization of the engineered implants in vivo. Endothelial cell spheroids were cocultured with hOBs in fibrin and seeded into scaffolds consisting of processed bovine cancellous bone (PBCB). The cell-seeded scaffolds were evaluated for their angiogenic potential in two different in vivo assays: the chick embryo chorioallantoic membrane (CAM) model and the severe combined immunodeficiency disorder (SCID) mouse model. In both assays, the development of a complex three-dimensional network of perfused human neovessels could be detected. After subcutaneous implantation into immunodeficient mice, the newly formed human vasculature was stabilized by the recruitment of murine smooth muscle α-actin-positive mural cells and anastomoses with the mouse vasculature. We conclude that this endothelial cell spheroid system can be used to create a network of functional perfused blood vessels in vivo. The finding that this process takes place with high efficacy in the presence of co-implanted primary osteoblasts and in an osteoconductive environment provided by the PBCB scaffold, suggests that this system may be suitable for improving vascularization in bone tissue engineering.
format Online
Article
Text
id pubmed-4516493
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-45164932015-08-03 In vivo engineering of a human vasculature for bone tissue engineering applications Steffens, Lilian Wenger, Andreas Stark, G Björn Finkenzeller, Günter J Cell Mol Med Tissue Engineering The neovascularization of three-dimensional voluminous tissues, such as bone, represents an important challenge in tissue engineering applications. The formation of a preformed vascular plexus could maintain cell viability and promote vascularization after transplantation. We have developed a three-dimensional spheroidal coculture system consisting of human primary endothelial cells and human primary osteoblasts (hOBs) to improve angiogenesis in bone tissue engineering applications. In this study, we investigated the survival and vascularization of the engineered implants in vivo. Endothelial cell spheroids were cocultured with hOBs in fibrin and seeded into scaffolds consisting of processed bovine cancellous bone (PBCB). The cell-seeded scaffolds were evaluated for their angiogenic potential in two different in vivo assays: the chick embryo chorioallantoic membrane (CAM) model and the severe combined immunodeficiency disorder (SCID) mouse model. In both assays, the development of a complex three-dimensional network of perfused human neovessels could be detected. After subcutaneous implantation into immunodeficient mice, the newly formed human vasculature was stabilized by the recruitment of murine smooth muscle α-actin-positive mural cells and anastomoses with the mouse vasculature. We conclude that this endothelial cell spheroid system can be used to create a network of functional perfused blood vessels in vivo. The finding that this process takes place with high efficacy in the presence of co-implanted primary osteoblasts and in an osteoconductive environment provided by the PBCB scaffold, suggests that this system may be suitable for improving vascularization in bone tissue engineering. John Wiley & Sons, Ltd 2009-09 2008-07-09 /pmc/articles/PMC4516493/ /pubmed/18624770 http://dx.doi.org/10.1111/j.1582-4934.2008.00418.x Text en © 2008 The Authors Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
spellingShingle Tissue Engineering
Steffens, Lilian
Wenger, Andreas
Stark, G Björn
Finkenzeller, Günter
In vivo engineering of a human vasculature for bone tissue engineering applications
title In vivo engineering of a human vasculature for bone tissue engineering applications
title_full In vivo engineering of a human vasculature for bone tissue engineering applications
title_fullStr In vivo engineering of a human vasculature for bone tissue engineering applications
title_full_unstemmed In vivo engineering of a human vasculature for bone tissue engineering applications
title_short In vivo engineering of a human vasculature for bone tissue engineering applications
title_sort in vivo engineering of a human vasculature for bone tissue engineering applications
topic Tissue Engineering
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516493/
https://www.ncbi.nlm.nih.gov/pubmed/18624770
http://dx.doi.org/10.1111/j.1582-4934.2008.00418.x
work_keys_str_mv AT steffenslilian invivoengineeringofahumanvasculatureforbonetissueengineeringapplications
AT wengerandreas invivoengineeringofahumanvasculatureforbonetissueengineeringapplications
AT starkgbjorn invivoengineeringofahumanvasculatureforbonetissueengineeringapplications
AT finkenzellergunter invivoengineeringofahumanvasculatureforbonetissueengineeringapplications